skip to main content
UK Health Security Agency

PEO1

PEO1

Catalogue No.

10032308

Cell Line Name

PEO1

Cell Line Description

PEO1 is an adherent cell line derived from a malignant effusion from the peritoneal ascites of a patient with a hereditary heterozygous BRCA2 mutation (5193C>G (Y1655X)) who developed a poorly differentiated serous ovarian adenocarcinoma. The patient had previously received cisplatin, 5-fluorouracil and chlorambucil treatment and the PEO1 cell line was isolated before the tumour acquired resistance to chemotherapy.

The cell line is tumourigenic in immunologically-deprived CBA mice. PEO1 exhibits good growth in a semi-solid medium (agar).

PEO1 is derived from the same patient as PEO4 (ECACC 10032309), PEO6 (ECACC 10032310) and PEO1-CDDP (ECACC 16012001). PEO4 and PEO6 were derived after the tumour had developed chemotherapeutic resistance and have a secondary mutation (5193C>T (Y1655Y)) that corrects the inherited BRCA2 mutation seen in PEO1. The PEO1-CDDP cell line is resistant to cisplatin but in contrast to PEO4 and PEO6, it was derived in vitro from PEO1 through exposure to increasing concentrations of cisplatin. PEO1-CDDP also has a secondary corrective BRCA2 mutation (5192A>T) different to the mutation seen in PEO4 and PEO6.

Please be aware that the originating laboratory of the PEO1 cell line acknowledges that PEO1 is both genetically unstable and derived from a heterogeneous population that was already present in the patient at the time of biopsy. This is evident in the literature (Cooke et al., 2010). Genetic differences within the PEO1 PEO4 and PEO6 cell lines suggest that PEO4 and PEO6 are not direct descendants of PEO1 but have diverged from a common ancestor

General Info

Species

Human

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Receptors

Oestrogen receptor positive cell line. For antigen expression see Langdon SP et.al. (1988) Cancer Research Nov 1; 48(21):6166-72.

Tissue of Origin

Ovary

Morphology

Islands of uniform polygonal cells

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 10,12
D5S818: 11,12
D7S820: 10
D13S317: 10
D16S539: 9
TH01: 9.3
TPOX: 9,11
vWA: 15,16

Karyotype

For modal chromosome numbers see Langdon SP et.al. (1988) Cancer Research Nov 1; 48(21):6166-72.

Disease

Cystadenocarcinoma

Culture Conditions

Cell Type

Epithelial

Subculture Routine

Split sub-confluent cultures (70-80%) 1:4 to 1:10 seeding at 2- 3 x 10⁴ cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C. Doubling time approximately 37 hours.

Culture Medium

RPMI -1640 + 2mM Glutamine + 2mM Sodium Pyruvate + 10% Foetal Bovine Serum (FBS).

Growth Mode

Adherent

Additional Info

Depositor

CancerTools (formerly known as Cancer Research Technologies Limited and Ximbio)

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Langdon SP et.al. (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Research Nov 1; 48(21):6166-72. PMID: 3167863.

Bibliography

Langdon SP et.al. (1990) Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. British Journal of Cancer Aug; 62(2):213-6. PMID: 2386737.

 

Langdon SP et.al (1988) Effect of sodium butyrate and other differentiation inducers on poorly differentiated human ovarian adenocarcinoma cell lines. Cancer Research Nov 1; 48(21):6161-5. PMID: 3167862.

 

Sakai W et al. (2009) Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 2009 August 15; 69(16): 6381–6386. PMID: 19654294.

 

Cooke SL et al. (2010) Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma PMID: 20581869.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: PEO1 (ECACC 10032308).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.